Abstract
XR5944 is a potent anticancer drug with a novel DNA binding mode: DNA bisintercalationg with major groove binding. XR5944 can bind the estrogen response element (ERE) sequence to block ER-ERE binding and inhibit ERα activities, which may be useful for overcoming drug resistance to currently available antiestrogen treatments. This review discusses the progress relating to the structure and function studies of specific DNA recognition of XR5944. The sites of intercalation within a native promoter sequence appear to be different from the ideal binding site and are context- and sequence- dependent. The structural information may provide insights for rational design of improved EREspecific XR5944 derivatives, as well as of DNA bis-intercalators in general.
Keywords: Anticancer drug, DNA bis-intercalation, DNA bis-intercalation with major groove binding, NMR solution structure, XR5944 or MLN944.
Graphical Abstract
Current Topics in Medicinal Chemistry
Title:DNA Recognition by a Novel Bis-Intercalator, Potent Anticancer Drug XR5944
Volume: 15 Issue: 14
Author(s): Clement Lin and Danzhou Yang
Affiliation:
Keywords: Anticancer drug, DNA bis-intercalation, DNA bis-intercalation with major groove binding, NMR solution structure, XR5944 or MLN944.
Abstract: XR5944 is a potent anticancer drug with a novel DNA binding mode: DNA bisintercalationg with major groove binding. XR5944 can bind the estrogen response element (ERE) sequence to block ER-ERE binding and inhibit ERα activities, which may be useful for overcoming drug resistance to currently available antiestrogen treatments. This review discusses the progress relating to the structure and function studies of specific DNA recognition of XR5944. The sites of intercalation within a native promoter sequence appear to be different from the ideal binding site and are context- and sequence- dependent. The structural information may provide insights for rational design of improved EREspecific XR5944 derivatives, as well as of DNA bis-intercalators in general.
Export Options
About this article
Cite this article as:
Lin Clement and Yang Danzhou, DNA Recognition by a Novel Bis-Intercalator, Potent Anticancer Drug XR5944, Current Topics in Medicinal Chemistry 2015; 15 (14) . https://dx.doi.org/10.2174/1568026615666150413155608
DOI https://dx.doi.org/10.2174/1568026615666150413155608 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Preface
Current Topics in Medicinal Chemistry Mesenchymal Stem Cells Neuronal Differentiation Ability: A Real Perspective for Nervous System Repair?
Current Stem Cell Research & Therapy Mechanism of Drug Sensitivity and Resistance in Melanoma
Current Cancer Drug Targets Meet Our Editorial Board Member
Letters in Drug Design & Discovery Potassium Channels are a New Target Field in Anticancer Drug Design
Recent Patents on Anti-Cancer Drug Discovery Suppressing Glioblastoma Stem Cell Function by Aldehyde Dehydrogenase Inhibition with Chloramphenicol or Disulfiram as a New Treatment Adjunct: A Hypothesis
Current Stem Cell Research & Therapy Administration of Drug and Nutritional Components in Nano-Engineered Form to Increase Delivery Ratio and Reduce Current Inefficient Practice
Recent Patents on Drug Delivery & Formulation Can We Select Patients for Colorectal Cancer Prevention with Aspirin?
Current Pharmaceutical Design SPECT-CT in Radiotherapy Planning, with Main Reference to Patients with Breast Cancer
Current Radiopharmaceuticals Nanoparticle- and Liposome-carried Drugs: New Strategies for Active Targeting and Drug Delivery Across Blood-brain Barrier
Current Drug Metabolism Publishing Orthology and Diseases Information in the Linked Open Data Cloud
Current Bioinformatics Synthetic Lethality to Overcome Cancer Drug Resistance
Current Medicinal Chemistry Melatonin and Melatoninergic Drugs as Therapeutic Agents: Ramelteon and Agomelatine, the Two Most Promising Melatonin Receptor Agonists
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Blood-Brain Barrier and Breast Cancer Resistance Protein: A Limit to the Therapy of CNS Tumors and Neurodegenerative Diseases
Anti-Cancer Agents in Medicinal Chemistry Solid Lipid Nanoparticles Containing Nimesulide: Preparation, Characterization and Cytotoxicity Studies
Current Nanoscience Application of DODMA and Derivatives in Cationic Nanocarriers for Gene Delivery
Current Organic Chemistry Therapeutic Strategies to Target Multiple Kinases in Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Role of Sulfur Containing Amino Acids as an Adjuvant Therapy in the Prevention of Diabetes and its Associated Complications
Current Diabetes Reviews First Total Synthesis of ω-Phenyl Δ6 Fatty Acids and their Leishmanicidal and Anticancer Properties
Current Topics in Medicinal Chemistry CypA: A Potential Target of Tumor Radiotherapy and/or Chemotherapy
Current Medicinal Chemistry